Table of Content

1.  Introduction
   1.1.  Market Definition
   1.2.  Market Ecosystem
   1.3.  Currency & Limitations
   1.4.  Key Stakeholders

2.  Research Methodology
   2.1.  Research Process
   2.2.  Data Collection & Validation Process
      2.2.1.  Secondary Research
      2.2.2.  Primary Research
   2.3.  Market Sizing & Forecasting
      2.3.1.  Market Size Estimation Approach
      2.3.2.  Growth Forecast Approach
   2.4.  Assumptions for the Study

3.  Executive Summary

4.  Market Insights
   4.1.  Overview
   4.2.  Factors Affecting Market Growth
      4.2.1.  Drivers
         4.2.1.1.  Growing Incidence of Cancer
         4.2.1.2.  Increasing Investments & Funding for MRD Testing & Research
      4.2.2.  Restraints
         4.2.2.1.  High Costs of Minimal Residual Disease Testing
      4.2.3.  Opportunities
         4.2.3.1.  Rising Adoption of Personalized Treatments & Targeted Therapies In the Field of Oncology
         4.2.3.2.  Growing Use of MRD Testing In Cases of Solid Tumors
      4.2.4.  Challenges
         4.2.4.1.  Chances of False Positive/Negative Results
      4.2.5.  Trends
         4.2.5.1.  Emergence of Digital PCR
         4.2.5.2.  Use of Mass Spectrometry for MRD Testing
         4.2.5.3.  Integration of Single-Cell Multiomics & Artificial Intelligence Into Minimal Residual Disease Testing
      4.2.6.  Factors Analysis
   4.3.  Regulatory Analysis
      4.3.1.  North America
         4.3.1.1.  U.S.
         4.3.1.2.  Canada
      4.3.2.  Europe
      4.3.3.  Asia-Pacific
         4.3.3.1.  China
         4.3.3.2.  Japan
         4.3.3.3.  India
      4.3.4.  Latin America
      4.3.5.  Middle East
   4.4.  Porter’s Five Forces Analysis
      4.4.1.  Bargaining Power of Buyers
      4.4.2.  Bargaining Power of Suppliers
      4.4.3.  Threat of Substitutes
      4.4.4.  Threat of New Entrants
      4.4.5.  Degree of Competition
   4.5.  Technology Evolution Roadmap

5.  Minimal Residual Disease Testing Market Assessment? By Offering
   5.1.  Overview
   5.2.  Assays & Reagents
   5.3.  Instruments
   5.4.  Software & Services

6.  Minimal Residual Disease Testing Market Assessment? By Technology
   6.1.  Overview
   6.2.  Flow Cytometry
   6.3.  Polymerase Chain Reaction
   6.4.  Next-Generation Sequencing
   6.5.  Other Technologies

7.  Minimal Residual Disease Testing Market Assessment? By Application
   7.1.  Overview
   7.2.  Blood Cancers
      7.2.1.  Lymphoma
      7.2.2.  Leukemia
         7.2.2.1.  Acute Lymphoblastic Leukemia (ALL)
         7.2.2.2.  Chronic Lymphocytic Leukemia (CLL)
         7.2.2.3.  Other Leukemias
      7.2.3.  Multiple Myeloma
      7.2.4.  Other Blood Cancers
   7.3.  Solid Tumors

8.  Minimal Residual Disease Testing Market Assessment? By Sample Type
   8.1.  Overview
   8.2.  Blood
   8.3.  Bone Marrow
   8.4.  Other Sample Types

9.  Minimal Residual Disease Testing Market Assessment? By Customer Type
   9.1.  Overview
   9.2.  Pharmaceutical & Biopharmaceutical Companies
   9.3.  Hospitals
   9.4.  Diagnostic Laboratories
   9.5.  Academic & Research Organizations/Institutions

10.  Minimal Residual Disease Testing Market Assessment? By Geography
   10.1.  Overview
   10.2.  North America
      10.2.1.  U.S.
      10.2.2.  Canada
   10.3.  Europe
      10.3.1.  Germany
      10.3.2.  U.K.
      10.3.3.  France
      10.3.4.  Italy
      10.3.5.  Spain
      10.3.6.  Switzerland
      10.3.7.  Netherlands
      10.3.8.  Rest of Europe
   10.4.  Asia-Pacific
      10.4.1.  China
      10.4.2.  Japan
      10.4.3.  India
      10.4.4.  South Korea
      10.4.5.  Australia
      10.4.6.  Rest of Asia-Pacific
   10.5.  Latin America
      10.5.1.  Brazil
      10.5.2.  Mexico
      10.5.3.  Rest of Latin America
   10.6.  Middle East & Africa

11.  Competitive Landscape
   11.1.  Overview
   11.2.  Key Growth Strategies
   11.3.  Competitive Benchmarking
   11.4.  Competitive Dashboard
      11.4.1.  Industry Leaders
      11.4.2.  Market Differentiators
      11.4.3.  Vanguards
      11.4.4.  Emerging Companies
   11.5.  Market Share Analysis (2023)
      11.5.1.  Natera Inc. (U.S.)
      11.5.2.  Bio-Rad Laboratories, Inc. (U.S.)
      11.5.3.  F. Hoffmann-La Roche Ltd. (Switzerland)
      11.5.4.  Adaptive Biotechnologies Corporation (U.S.)

12.  Company Profiles
   12.1.  Natera Inc.
   12.2.  Bio-Rad Laboratories, Inc.
   12.3.  F. Hoffmann-La Roche Ltd.
   12.4.  Adaptive Biotechnologies Corporation
   12.5.  Illumina, Inc.
   12.6.  Thermo Fisher Scientific, Inc.
   12.7.  Qiagen N.V.
   12.8.  Integrated DNA Technologies, Inc. (U.S.) (A Subsidiary of Danaher Corporation [U.S.])
   12.9.  Twist Bioscience Corporation
   12.10.  Sysmex Corporation
   12.11.  Invivoscribe, Inc.
13.  Appendix
   13.1.  Available Customization
   13.2.  Related Reports



List of Figures

Figure 1?? ?Market Ecosystem
Figure 2?? ?Research Process
Figure 3?? ?Secondary Sources Referenced for This Study
Figure 4?? ?Primary Research Techniques
Figure 5?? ?Key Executives Interviewed
Figure 6?? ?Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7?? ?Market Sizing & Growth Forecast Approach
Figure 8?? ?Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)?? ?
Figure 9?? ?Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)?? ?
Figure 10?? ?Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)?? ?
Figure 11?? ?Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)?? ?
Figure 12?? ?Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
Figure 13?? ?Global Minimal Residual Disease Testing Market, By Geography
Figure 14?? ?Impact Analysis of Market Dynamics
Figure 15?? ?USFDA Regulatory Pathways for IVD Products
Figure 16?? ?Eu Regulatory Pathway - IVDR 2017/746
Figure 17?? ?China: Medical Device Classification and Pre-Market Requirements for MRD Testing Instruments
Figure 18?? ?Saudi Arabia: Medical Device - Marketing Authorization Process
Figure 19?? ?Porter’s Five Forces Analysis
Figure 20?? ?Minimal Residual Disease Testing: Technology Evolution Roadmap
Figure 21?? ?Global Minimal Residual Disease Testing Market, By Offering, 2024 Vs. 2031 (USD Million)?? ?
Figure 22?? ?Global Minimal Residual Disease Testing Market, By Technology, 2024 Vs. 2031 (USD Million)?? ?
Figure 23?? ?Global Minimal Residual Disease Testing Market, By Application, 2024 Vs. 2031 (USD Million)?? ?
Figure 24?? ?Global Minimal Residual Disease Testing Market, By Sample Type, 2024 Vs. 2031 (USD Million)?? ?
Figure 25?? ?Global Minimal Residual Disease Testing Market, By Customer Type, 2024 Vs. 2031 (USD Million)
Figure 26?? ?Global Minimal Residual Disease Testing Market, By Geography, 2024 Vs. 2031 (USD Million)?? ?
Figure 27?? ?North America: Minimal Residual Disease Testing Market Snapshot
Figure 28?? ?Europe: Minimal Residual Disease Testing Market Snapshot
Figure 29?? ?U.K.: Number of New Cancer Cases, 2022?2040
Figure 30?? ?France: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 31?? ?Switzerland: Number of New Cancer Cases, 2022?2040
Figure 32?? ?Netherlands: Number of New Cancer Cases, 2022?2040
Figure 33?? ?Asia-Pacific: Minimal Residual Disease Testing Market Snapshot
Figure 34?? ?South Korea: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 35?? ?Latin America: Minimal Residual Disease Testing Market Snapshot
Figure 36?? ?Mexico: Incidence of Leukemia, Lymphoma, and Myeloma, 2022 Vs. 2030
Figure 37?? ?Middle East & Africa: Number of New Cancer Cases, By Country, 2022 Vs. 2030
Figure 38?? ?Key Growth Strategies Adopted By Leading Players, 2021-2024
Figure 39?? ?Minimal Residual Disease Testing Market: Competitive Benchmarking, By Technology?? ?
Figure 40?? ?Minimal Residual Disease Testing Market: Competitive Benchmarking, By Region
Figure 41?? ?Competitive Dashboard: Minimal Residual Disease Testing Market
Figure 42?? ?Global Minimal Residual Disease Testing Market Share Analysis, By Key Players (2023)
Figure 43?? ?Natera Inc.: Financial Overview (2023)
Figure 44?? ?Bio-Rad Laboratories, Inc.: Financial Overview (2023)
Figure 45?? ?F. Hoffmann-La Roche Ltd.: Financial Overview (2023)
Figure 46?? ?Adaptive Biotechnologies Corporation.: Financial Overview (2023)
Figure 47?? ?Illumina Inc.: Financial Overview (2023)
Figure 48?? ?Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 49?? ?Qiagen N.V.: Financial Overview (2023)
Figure 50?? ?Danaher Corporation: Financial Overview (2023)
Figure 51?? ?Twist Bioscience Corporation: Financial Overview (2023)
Figure 52?? ?Sysmex Corporation: Financial Overview (2024)